A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to
assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and
adolescent patients with active eosinophilic esophagitis. Subjects who complete the
randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses
of open-label lirentelimab (AK002) through the OLE Period of the study.